Carbohydrate Metabolism, Inborn Errors
Welcome,         Profile    Billing    Logout  
 27 Companies   22 Products   22 Products   0 Mechanisms of Action   3 Trials   275 News 
3 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Carbohydrate Metabolism, Inborn Errors
NCT02097251: An Open-Label Treatment Protocol With UX003 rhGUS Enzyme Replacement Therapy for an Advanced Stage MPS 7 Patient

No Longer Available
N/A
US
UX003, recombinant human beta glucuronidase, rhGUS
Joyce Fox, Ultragenyx Pharmaceutical Inc
Mucopolysaccharidosis Type 7
 
 
NCT02018302: Post Study Continuation of C7 for G1D

No Longer Available
N/A
US
Triheptanoin, C7 oil, Heptanoate, heptanoic acid
Juan Pascual
Glut1 Deficiency Syndrome, Glucose Transporter Type 1 Deficiency Syndrome
 
 
NCT02399748: A Long-term Study for the Outcome of Pompe Disease

Recruiting
N/A
50
RoW
National Taiwan University Hospital
Pompe Disease
12/26
12/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Carbohydrate Metabolism, Inborn Errors
NCT02097251: An Open-Label Treatment Protocol With UX003 rhGUS Enzyme Replacement Therapy for an Advanced Stage MPS 7 Patient

No Longer Available
N/A
US
UX003, recombinant human beta glucuronidase, rhGUS
Joyce Fox, Ultragenyx Pharmaceutical Inc
Mucopolysaccharidosis Type 7
 
 
NCT02018302: Post Study Continuation of C7 for G1D

No Longer Available
N/A
US
Triheptanoin, C7 oil, Heptanoate, heptanoic acid
Juan Pascual
Glut1 Deficiency Syndrome, Glucose Transporter Type 1 Deficiency Syndrome
 
 
NCT02399748: A Long-term Study for the Outcome of Pompe Disease

Recruiting
N/A
50
RoW
National Taiwan University Hospital
Pompe Disease
12/26
12/26

Download Options